Suraksha Diagnostic Company Secretary resigns effective July 15

Suraksha Diagnostic Limited announced the resignation of Ms. Mamta Jain from the position of Company Secretary & Compliance Officer and Key Managerial Personnel (KMP). The resignation, effective July 15, 2026, was tendered on June 9, 2026, and is attributed to personal reasons. The company confirmed there are no other material reasons for her departure.

The disclosure was made to BSE Limited and The National Stock Exchange of India Limited under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company acknowledged her contributions during her tenure.

Resignation Details

The company provided specific details regarding the cessation of the role in a structured format as required by SEBI regulations.

Detail	Information
Reason for change	Resignation due to personal reasons
Date of cessation	15 July 2026 (close of business hours)
Brief profile	Not Applicable
Disclosure of relationship	Not Applicable

Ms. Jain confirmed in her resignation letter that she will extend full cooperation to ensure a smooth transition of her responsibilities. The company has undertaken necessary statutory and regulatory filings regarding the change.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-2.19%	-4.28%	-7.73%	-1.14%	-19.59%	-35.37%

Suraksha Diagnostic Limited has reported its audited standalone and consolidated financial results for the quarter and financial year ended 31 March 2026. The company achieved a total revenue of INR3,136 million for FY26, registering a year-on-year growth of 22.5% compared to INR2,559 million in FY25. Profit after tax for the year stood at INR314 million, reflecting a 1.4% increase from the previous year. The Board of Directors recommended a dividend of ₹0.50 per equity share for FY26, subject to shareholder approval, with the record date fixed for Wednesday, 26 August 2026.

Q4 and FY26 Financial Performance

For the fourth quarter of FY26, the company reported a total revenue of INR822 million compared to INR659 million in Q4 FY25, a growth of 25%. EBITDA for Q4 FY26 stood at INR252 million compared to INR200 million in the same period last year, with the EBITDA margin remaining stable at 31%. PAT for the quarter was INR62 million, up from INR22 million in Q4 FY25. On a full-year basis, EBITDA increased by 15.8% year-on-year to INR986 million, while the EBITDA margin for FY26 was 31.8% compared to 33.8% in FY25.

Metric	FY26	FY25
Total Revenue	INR3,136 million	INR2,559 million
EBITDA	INR986 million	INR851 million
EBITDA Margin	31.8%	33.8%
Profit After Tax	INR314 million	INR310 million

Operational Highlights and Expansion

Suraksha served 1.37 million patients in FY26, executing 8.16 million clinical tests. The revenue per patient increased to INR2,264, driven by a shift towards specialized diagnostics and advanced radiology. Pathology contributed 48.85% of operational revenue, while radiology contributed 44.26%. The company expanded its network during the year, adding two hub centers, 11 spoke centers, and three centers under the PPP model, bringing the total count to 68 centers as of March 2026.

Management outlined the strategic focus for FY27, which includes expanding footprint across eastern and northeastern India. The company plans to establish three new hubs and eight asset-light spoke centers within West Bengal, and launch one specialized hub center each in Bihar, Tripura, and Jharkhand. The total planned capex for this rollout is around INR70 crores.

Corporate Actions

The board approved the notice convening the 21st Annual General Meeting (AGM), scheduled for Wednesday, 02 September 2026, via video conferencing. Additionally, the board approved the re-appointment of M/s. S Chhaparia & Associates as Cost Auditor for FY 2026-27 and appointed M/s. Suresh Surana & Associates LLP as the Internal Auditor for the financial year 2026-27. The text transcript of the earnings call held on 22 May 2026 is available on the company's website.